Monophosphoryl lipid a induces protection against lps in medullary thick ascending limb through a tlr4-trif-pi3k signaling pathway

Bruns Watts, Thampi George, Edward R. Sherwood, David Good

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Monophosphoryl lipid A (MPLA) is a detoxified derivative of LPS that induces tolerance to LPS and augments host resistance to bacterial infections. Previously, we demonstrated that LPS inhibits HCO3 - absorption in the medullary thick ascending limb (MTAL) through a basolateral Toll-like receptor 4 (TLR4)-myeloid differentiation factor 88 (MyD88)-ERK pathway. Here we examined whether pretreatment with MPLA would attenuate LPS inhibition. MTALs from rats were perfused in vitro with MPLA (1 μg/ml) in bath and lumen or bath alone for 2 h, and then LPS was added to (and MPLA removed from) the bath solution. Pretreatment with MPLA eliminated LPS-induced inhibition of HCO3 - absorption. In MTALs pretreated with MPLA plus a phosphatidylinositol 3-kinase (PI3K) or Akt inhibitor, LPS decreased HCO- 3 absorption. MPLA increased Akt phosphorylation in dissected MTALs. The Akt activation was eliminated by a PI3K inhibitor and in MTALs from TLR4-/- or Toll/IL-1 receptor domain-containing adaptor-inducing IFN-β (TRIF)-/- mice. The effect of MPLA to prevent LPS inhibition of HCO- 3 absorption also was TRIF dependent. Pretreatment with MPLA prevented LPS-induced ERK activation; this effect was dependent on PI3K. MPLA alone had no effect on HCO- 3 absorption, and MPLA pretreatment did not prevent ERK-mediated inhibition of HCO3 - absorption by aldosterone, consistent with MPLA’s low toxicity profile. These results demonstrate that pretreatment with MPLA prevents the effect of LPS to inhibit HCO- 3 absorption in the MTAL. This protective effect is mediated directly through MPLA stimulation of a TLR4-TRIF-PI3K-Akt pathway that prevents LPS-induced ERK activation. These studies identify detoxified TLR4-based immuno-modulators as novel potential therapeutic agents to prevent or treat renal tubule dysfunction in response to bacterial infections.

Original languageEnglish (US)
Pages (from-to)F103-F115
JournalAmerican Journal of Physiology - Renal Physiology
Volume313
Issue number1
DOIs
StatePublished - Jul 7 2017

Fingerprint

Extremities
Lipids
Phosphatidylinositol 3-Kinase
Toll-Like Receptor 4
Baths
Bacterial Infections
monophosphoryl lipid A
Myeloid Differentiation Factor 88
Interleukin-1 Receptors
MAP Kinase Signaling System
Aldosterone
Phosphorylation
Kidney

Keywords

  • Kidney
  • LPS
  • Monophosphoryl lipid A
  • Sepsis
  • Toll-like receptor 4

ASJC Scopus subject areas

  • Physiology
  • Urology

Cite this

Monophosphoryl lipid a induces protection against lps in medullary thick ascending limb through a tlr4-trif-pi3k signaling pathway. / Watts, Bruns; George, Thampi; Sherwood, Edward R.; Good, David.

In: American Journal of Physiology - Renal Physiology, Vol. 313, No. 1, 07.07.2017, p. F103-F115.

Research output: Contribution to journalArticle

@article{5defc33790894ec09d716c8090c5cdfd,
title = "Monophosphoryl lipid a induces protection against lps in medullary thick ascending limb through a tlr4-trif-pi3k signaling pathway",
abstract = "Monophosphoryl lipid A (MPLA) is a detoxified derivative of LPS that induces tolerance to LPS and augments host resistance to bacterial infections. Previously, we demonstrated that LPS inhibits HCO3 - absorption in the medullary thick ascending limb (MTAL) through a basolateral Toll-like receptor 4 (TLR4)-myeloid differentiation factor 88 (MyD88)-ERK pathway. Here we examined whether pretreatment with MPLA would attenuate LPS inhibition. MTALs from rats were perfused in vitro with MPLA (1 μg/ml) in bath and lumen or bath alone for 2 h, and then LPS was added to (and MPLA removed from) the bath solution. Pretreatment with MPLA eliminated LPS-induced inhibition of HCO3 - absorption. In MTALs pretreated with MPLA plus a phosphatidylinositol 3-kinase (PI3K) or Akt inhibitor, LPS decreased HCO- 3 absorption. MPLA increased Akt phosphorylation in dissected MTALs. The Akt activation was eliminated by a PI3K inhibitor and in MTALs from TLR4-/- or Toll/IL-1 receptor domain-containing adaptor-inducing IFN-β (TRIF)-/- mice. The effect of MPLA to prevent LPS inhibition of HCO- 3 absorption also was TRIF dependent. Pretreatment with MPLA prevented LPS-induced ERK activation; this effect was dependent on PI3K. MPLA alone had no effect on HCO- 3 absorption, and MPLA pretreatment did not prevent ERK-mediated inhibition of HCO3 - absorption by aldosterone, consistent with MPLA’s low toxicity profile. These results demonstrate that pretreatment with MPLA prevents the effect of LPS to inhibit HCO- 3 absorption in the MTAL. This protective effect is mediated directly through MPLA stimulation of a TLR4-TRIF-PI3K-Akt pathway that prevents LPS-induced ERK activation. These studies identify detoxified TLR4-based immuno-modulators as novel potential therapeutic agents to prevent or treat renal tubule dysfunction in response to bacterial infections.",
keywords = "Kidney, LPS, Monophosphoryl lipid A, Sepsis, Toll-like receptor 4",
author = "Bruns Watts and Thampi George and Sherwood, {Edward R.} and David Good",
year = "2017",
month = "7",
day = "7",
doi = "10.1152/ajprenal.00064.2017",
language = "English (US)",
volume = "313",
pages = "F103--F115",
journal = "American Journal of Physiology - Endocrinology and Metabolism",
issn = "0193-1849",
publisher = "American Physiological Society",
number = "1",

}

TY - JOUR

T1 - Monophosphoryl lipid a induces protection against lps in medullary thick ascending limb through a tlr4-trif-pi3k signaling pathway

AU - Watts, Bruns

AU - George, Thampi

AU - Sherwood, Edward R.

AU - Good, David

PY - 2017/7/7

Y1 - 2017/7/7

N2 - Monophosphoryl lipid A (MPLA) is a detoxified derivative of LPS that induces tolerance to LPS and augments host resistance to bacterial infections. Previously, we demonstrated that LPS inhibits HCO3 - absorption in the medullary thick ascending limb (MTAL) through a basolateral Toll-like receptor 4 (TLR4)-myeloid differentiation factor 88 (MyD88)-ERK pathway. Here we examined whether pretreatment with MPLA would attenuate LPS inhibition. MTALs from rats were perfused in vitro with MPLA (1 μg/ml) in bath and lumen or bath alone for 2 h, and then LPS was added to (and MPLA removed from) the bath solution. Pretreatment with MPLA eliminated LPS-induced inhibition of HCO3 - absorption. In MTALs pretreated with MPLA plus a phosphatidylinositol 3-kinase (PI3K) or Akt inhibitor, LPS decreased HCO- 3 absorption. MPLA increased Akt phosphorylation in dissected MTALs. The Akt activation was eliminated by a PI3K inhibitor and in MTALs from TLR4-/- or Toll/IL-1 receptor domain-containing adaptor-inducing IFN-β (TRIF)-/- mice. The effect of MPLA to prevent LPS inhibition of HCO- 3 absorption also was TRIF dependent. Pretreatment with MPLA prevented LPS-induced ERK activation; this effect was dependent on PI3K. MPLA alone had no effect on HCO- 3 absorption, and MPLA pretreatment did not prevent ERK-mediated inhibition of HCO3 - absorption by aldosterone, consistent with MPLA’s low toxicity profile. These results demonstrate that pretreatment with MPLA prevents the effect of LPS to inhibit HCO- 3 absorption in the MTAL. This protective effect is mediated directly through MPLA stimulation of a TLR4-TRIF-PI3K-Akt pathway that prevents LPS-induced ERK activation. These studies identify detoxified TLR4-based immuno-modulators as novel potential therapeutic agents to prevent or treat renal tubule dysfunction in response to bacterial infections.

AB - Monophosphoryl lipid A (MPLA) is a detoxified derivative of LPS that induces tolerance to LPS and augments host resistance to bacterial infections. Previously, we demonstrated that LPS inhibits HCO3 - absorption in the medullary thick ascending limb (MTAL) through a basolateral Toll-like receptor 4 (TLR4)-myeloid differentiation factor 88 (MyD88)-ERK pathway. Here we examined whether pretreatment with MPLA would attenuate LPS inhibition. MTALs from rats were perfused in vitro with MPLA (1 μg/ml) in bath and lumen or bath alone for 2 h, and then LPS was added to (and MPLA removed from) the bath solution. Pretreatment with MPLA eliminated LPS-induced inhibition of HCO3 - absorption. In MTALs pretreated with MPLA plus a phosphatidylinositol 3-kinase (PI3K) or Akt inhibitor, LPS decreased HCO- 3 absorption. MPLA increased Akt phosphorylation in dissected MTALs. The Akt activation was eliminated by a PI3K inhibitor and in MTALs from TLR4-/- or Toll/IL-1 receptor domain-containing adaptor-inducing IFN-β (TRIF)-/- mice. The effect of MPLA to prevent LPS inhibition of HCO- 3 absorption also was TRIF dependent. Pretreatment with MPLA prevented LPS-induced ERK activation; this effect was dependent on PI3K. MPLA alone had no effect on HCO- 3 absorption, and MPLA pretreatment did not prevent ERK-mediated inhibition of HCO3 - absorption by aldosterone, consistent with MPLA’s low toxicity profile. These results demonstrate that pretreatment with MPLA prevents the effect of LPS to inhibit HCO- 3 absorption in the MTAL. This protective effect is mediated directly through MPLA stimulation of a TLR4-TRIF-PI3K-Akt pathway that prevents LPS-induced ERK activation. These studies identify detoxified TLR4-based immuno-modulators as novel potential therapeutic agents to prevent or treat renal tubule dysfunction in response to bacterial infections.

KW - Kidney

KW - LPS

KW - Monophosphoryl lipid A

KW - Sepsis

KW - Toll-like receptor 4

UR - http://www.scopus.com/inward/record.url?scp=85022339046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85022339046&partnerID=8YFLogxK

U2 - 10.1152/ajprenal.00064.2017

DO - 10.1152/ajprenal.00064.2017

M3 - Article

VL - 313

SP - F103-F115

JO - American Journal of Physiology - Endocrinology and Metabolism

JF - American Journal of Physiology - Endocrinology and Metabolism

SN - 0193-1849

IS - 1

ER -